Orphan drug designation isreserved for medicines treating rare, life-threatening or chronically debilitating diseases
IgA nephropathy(IgAN), while rare,is the most common form ofglomerulonephritis, affectingmostly young adults with no approved treatment option and significant risk to progress to e …
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00English RSS Feedhttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngEnglish RSS Feed2020-10-23 06:15:002020-10-23 06:15:00Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
